Turbogen Ltd. Form 6-K — Sep 24, 2026
TurboGen (NASDAQ: TRBG) reported H1 2026 net loss of $4.2 million, a 45% improvement from $7.6 million a year earlier, driven mainly by a $6.4 million favorable swing in warrant fair-value and debt-extinguishment effects rather than operations. Operating loss more than doubled to $5.2 million from $2.3 million, with R&D up 192% to $1.9 million and G&A up 116% to $3.1 million on share-based compensation and Nasdaq listing costs. The company remains development-stage with zero revenue and does not expect meaningful revenue until end of 2026 at the earliest.
Key figures
- Total Assets
- 8073000
- Cash Position
- 7235000
- Shares Outstanding
- 22561622
- Ga expenses
- 3059000
- Rd expenses
- 1877000
- Nasdaq listing date
- 2026-08-31
- Shareholders equity
- 1629000
- Operating loss h1 2025
- 2261000
- Operating loss h1 2026
- 5217000
- Private placement shares
- 1131616
- Sales marketing expenses
- 281000
- Warrants liability june 30 2026
- 2040000
- Private placement price per share usd
- 4.42
- August private placement gross proceeds
- 5000000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.